Urolithin A and Perioperative Management
Urolithin A does not require discontinuation before surgery or regional anesthesia, as there is no evidence of anticoagulant effects or increased bleeding risk associated with this supplement.
Evidence Assessment
The FDA drug label for urolithin A 1 contains no warnings about anticoagulant properties, bleeding risk, or perioperative discontinuation requirements. The only contraindication listed is allergy to product components, with general guidance to discontinue if discomfort occurs during use.
Lack of Anticoagulant Properties
Urolithin A is a gut microbial metabolite of ellagic acid that has demonstrated neuroprotective, anti-inflammatory, and autophagy-promoting effects in various disease models 2, 3, 4. None of the available research evidence describes anticoagulant, antiplatelet, or blood-thinning properties. The compound's mechanisms of action involve:
- AMPK/mTOR/HIF-1α signaling pathway modulation 2
- AKT-FOXO1-mediated autophagy regulation 3
- Anti-inflammatory effects through microglial inhibition 4
- Enhancement of neurogenesis and synaptic plasticity 4
Context: Established Anticoagulant Management
For comparison, established anticoagulants and antiplatelet agents require specific perioperative management:
- DOACs (apixaban, rivaroxaban, dabigatran): Stop 1-2 days before low-moderate bleeding risk procedures, 2 days before high-risk procedures 5, 6
- Warfarin: Stop at least 5 days preoperatively 7
- Aspirin/Clopidogrel: Stop >7-10 days preoperatively 7
- NSAIDs: Stop 1-10 days depending on specific agent 7
Regional anesthesia guidelines emphasize careful coagulation assessment before neuraxial blockade 8, 9, 6, but these concerns apply to known anticoagulants, not urolithin A.
Clinical Recommendation
Continue urolithin A through the perioperative period without interruption. There is no pharmacological basis for concern about bleeding complications with regional anesthesia or surgery. The supplement does not appear in any perioperative anticoagulation guidelines 8, 10 and lacks the pharmacological properties that would necessitate discontinuation.
If a patient is taking urolithin A alongside actual anticoagulants or antiplatelet agents, manage those medications according to established guidelines while continuing urolithin A without restriction.